이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

국소 췌장암의 액체 생검(ctDNA) 유도 치료: 신보조 CTX 대 선행 수술 (LIQUIPANC)

2026년 10월 30일 업데이트: Patrick Kirchweger, Elisabethinen Hospital

국소 췌장암의 액체 생검 유도 치료(LIQUIPANC): 선행 화학요법과 선행 수술의 계층화를 위한 정밀 의학 도구로서의 순환 종양 DNA(ctDNA)

This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (CA 19-9 levels <500, no vessel contact and recommended by multidisciplinary tumor board). ctDNA positive patients are randomized to either receive neoadjvuant chemotherapy at current gold standard physicians choice vs. upfront surgery because of assumed high biological risk for early recurrence of ctDNA+. ctDNA- will receive upfront surgery in adherence to local guidelines.

연구 개요

상세 설명

Pancreatic ductal adenocarcinoma (PDAC) is characterized by high recurrence rates and poor long-term survival, even following potentially curative surgical resection and modern multimodal treatment. Despite improvements in surgical techniques, perioperative management, and systemic chemotherapy, a substantial proportion of patients with anatomically resectable PDAC experience early disease recurrence, suggesting the presence of occult systemic disease that cannot be adequately identified by conventional staging methods.

Current treatment decisions are primarily based on radiological resectability, clinical performance status, and established biomarkers such as carbohydrate antigen 19-9 (CA19-9). However, these parameters provide limited information about individual tumor biology and the risk of early recurrence. Consequently, patients with apparently favorable anatomical characteristics may still harbor biologically aggressive disease.

Circulating tumor DNA (ctDNA) has emerged as a promising minimally invasive biomarker for assessing tumor biology, monitoring treatment response, and predicting oncological outcomes. In previous studies, the investigators demonstrated that an early decrease in ctDNA levels of at least 42% after two weeks of systemic chemotherapy could predict subsequent radiological treatment response with high sensitivity and specificity, substantially earlier than conventional imaging (Kirchweger et al., Frontiers in Oncology, 2022). Furthermore, pretherapeutic ctDNA positivity in patients with localized PDAC was associated with significantly shorter disease-free survival (3.3 vs. 18.1 months), despite the absence of radiological evidence of advanced or metastatic disease (Kirchweger et al., European Journal of Surgical Oncology, 2021).

These findings suggest that pretherapeutic ctDNA detection may identify patients at increased risk of early recurrence who could potentially benefit from neoadjuvant systemic treatment, even when conventional clinical and radiological criteria favor upfront surgery.

However, a universal neoadjuvant treatment approach for all patients with anatomically resectable PDAC remains controversial. Although neoadjuvant chemotherapy may provide early systemic disease control and reveal aggressive tumor biology, it also exposes patients to treatment-related toxicity, potential deterioration in quality of life, and the risk of losing the opportunity for surgical resection due to disease progression or treatment intolerance. Therefore, a more individualized treatment strategy incorporating biological risk assessment may help optimize treatment sequencing.

The LIQUIPANC study is a prospective, multicenter, randomized clinical trial investigating the prognostic and potential clinical utility of ctDNA-guided treatment strategies in patients with anatomically resectable PDAC.

Eligible patients have localized PDAC without radiological vessel involvement, CA19-9 levels below 500 U/mL, and a multidisciplinary tumor board recommendation for upfront surgical resection based on conventional staging.

Following informed consent, approximately 30 mL of peripheral blood is collected before the initiation of oncological treatment. Plasma-derived ctDNA is analyzed using droplet digital polymerase chain reaction (ddPCR), primarily targeting KRAS G12/G13 mutations, with additional KRAS Q61 testing if the initial analysis is negative.

Treatment allocation is determined as follows:

ctDNA-positive patients: Patients with detectable ctDNA are randomized to one of two treatment strategies:

Neoadjuvant treatment arm: Patients receive neoadjuvant chemotherapy according to current standards of care and the treating physician's choice, followed by surgical resection when clinically feasible and subsequent treatment according to local guidelines.

Standard-of-care arm: Patients undergo upfront surgical resection, followed by adjuvant chemotherapy and further treatment according to current local guidelines and the treating physician's choice.

ctDNA-negative patients: Patients without detectable ctDNA are not randomized and undergo upfront surgical resection in accordance with the multidisciplinary tumor board recommendation and current local standards of care, followed by adjuvant treatment as indicated.

The randomized comparison among ctDNA-positive patients aims to investigate whether neoadjuvant chemotherapy, compared with upfront surgery, improves oncological outcomes in patients with potentially unfavorable tumor biology.

The overall study population will additionally be evaluated to investigate the prognostic significance of baseline ctDNA status and its association with disease recurrence and survival.

The primary endpoint is disease-free survival (DFS). Overall survival (OS) and the prognostic value of ctDNA detection are evaluated as additional outcomes.

LIQUIPANC aims to provide prospective clinical evidence regarding the feasibility and potential value of incorporating liquid biopsy into treatment decision-making for anatomically resectable PDAC. Ultimately, the study seeks to support a more personalized approach to treatment sequencing by identifying patients who may benefit from neoadjuvant systemic therapy while avoiding potentially unnecessary treatment delays and toxicity in others.

연구 유형

중재적

등록 (추정된)

100

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Upper Austria
      • Linz, Upper Austria, 오스트리아, 4010
        • Ordensklinikum Linz Barmherzige Schwestern

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Informed consent
  • >18 years old
  • localized pancreatic cancer to go for upfront surgery

Exclusion Criteria:

  • synchronous secondary malignancy
  • pregnancy

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: ctDNA+ _ctDNA guided

All patients enrolled in the study have anatomically resectable pancreatic ductal adenocarcinoma (PDAC), without radiological vessel involvement and with CA19-9 levels below 500 U/mL, and have been recommended for upfront surgical resection by a multidisciplinary tumor board.

Patients with detectable pretherapeutic circulating tumor DNA (ctDNA) are considered at increased biological risk for early disease recurrence and are randomized 1:1 to either neoadjuvant chemotherapy or upfront surgery.

Patients allocated to this experimental arm receive neoadjuvant chemotherapy according to current standards of care and the treating physician's choice, followed by surgical resection when clinically feasible and subsequent treatment according to local guidelines.

All patients included into the study are recommended to go for upfront surgery (CT and CA19-9) by tumor board.

If preoperative ctDNA is positive, the investigators assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.

  • Apart from blood collection (within the scope of clinical routine), there is no additional diagnostic intervention performed on the patient.
  • The respective neoadjuvant chemotherapeutical drug will be selected and applied by the treating medical oncologist at physicians choice (unaffected by study participation), usually mFOLFIRINOX or Gemcitabine/nabPaclitaxel at standardized dosage recommended by NCCN and local guidelines.

FOLFIRONOX: Folinic acid (also known as leucovorin), F - Fluorouracil (5-FU), IRIN - Irinotecan, OX - Oxaliplatin.

다른 이름들:
  • 실험적
다른: Standard of care

Patients assigned to this arm undergo upfront surgical resection as recommended by the multidisciplinary tumor board, followed by adjuvant chemotherapy and subsequent treatment according to current standards of care and the treating physician's choice.

This arm includes two prespecified patient subgroups:

ctDNA-positive patients randomized to upfront surgery as part of the randomized comparison with neoadjuvant chemotherapy.

ctDNA-negative patients assigned to upfront surgery without randomization, in accordance with standard treatment recommendations.

The primary randomized treatment comparison is restricted to ctDNA-positive patients. The ctDNA-negative subgroup is evaluated separately for exploratory analyses of the prognostic significance of baseline ctDNA status and oncological outcomes.

Standard of care as recommended by tumor board (not affected by study conditions).

다른 이름들:
  • 치료의 표준

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
DFS
기간: After 12 months

Disease free survival

After 12 months

2차 결과 측정

결과 측정
측정값 설명
기간
OS
기간: After 12 months

Overall survival

After 12 months
ctDNA detection rate
기간: Preoperatively

Detection rate of ctDNA in peripheral blood using a cost-effective and clinical applicable small spectrum ddPCR analysis in order to enable immediate clinical implementation

Preoperatively

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Patrick Kirchweger, MD, PhD, Ordensklinikum Linz, Department of Surgery

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 1월 11일

기본 완료 (실제)

2026년 6월 1일

연구 완료 (추정된)

2027년 6월 1일

연구 등록 날짜

최초 제출

2024년 4월 20일

QC 기준을 충족하는 최초 제출

2024년 4월 25일

처음 게시됨 (실제)

2024년 4월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 30일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다